Science4Data Article Insights

https://www.nytimes.com/2020/08/01/world/asia/coronavirus-vaccine-india.html?smtyp=cur&smid=tw-nytimes

Indian Billionaires Bet Big on Head Start in Coronavirus Vaccine Race

2020-08-01 00:00:00, Jeffrey Gettleman, New York Times

Content Categorization
/Pets & Animals
/Health/Health Conditions/Infectious Diseases
/Health/Public Health
/Hobbies & Leisure
/Health/Medical Facilities & Services/Medical Procedures

Word Count:
1978

Words/Sentence:
21

Reading Time:
13.19 min

Reading Quality:
Intermediate

Readability:
11th or 12th

Media Sentiment
Proprietary sentiment analysis on both the headline and body text of the article. Sentiment scores range from -1 (very negative sentiment) to 1 (very positive sentiment).
RCS Analysis
Relative scoring for Risk, Crisis, and Security language within the article.
Risk Score
Scoring based on the composite risk, security and crisis language within an article compared to a baseline of historic analysis across thousands of diverse articles.
PESTEL Scope
Analysis of article orientation across the PESTEL macro-environmental analysis framework. Learn more about PESTEL.
Entity Word Cloud
Key people, places, organizations and events referenced in the article, weighted by frequency and colored based on contextual sentiment.
Auto Summary
Condensing key features of the article based on salience analysis. Helpful for “gisting” the article in a time crunch.

It's also led by a highly nationalistic prime minister, Narendra Modi, whose government has already blocked exports of drugs that were believed to help treat Covid-19, the disease caused by the coronavirus.

Atul Loke for The New York TimesWith the coronavirus pandemic turning the world upside down and all hopes pinned on a vaccine, the Serum Institute finds itself in the middle of an extremely competitive and murky endeavor.

Scientists in white lab coats brought the vial to Building 14, carefully poured the contents into a flask, added a medium of vitamins and sugar and began growing billions of cells.

Adar Poonawalla, 39, says that he will split the hundreds of millions of vaccine doses he produces 50-50 between India and the rest of the world, with a focus on poorer countries, and that Mr. Modi's government has not objected to this.

National health ministers, prime ministers and other heads of state (he wouldn't say who) and friends he hasn't heard from in years have been calling him, he said, begging for the first batches."I've had to explain to them that, 'Look I can't just give it to you like this,'" he said.

Keywords
Vaccines Immunization, Oxford University, India, COVID-19, Serum Institute of India, Coronavirus, AstraZeneca, Clinical trial

Interested in Learning More?

Article Analysis is at the foundation of powerful media monitoring and insights. Learn what you can build with powerful curated search engines, real-time listening and trend analysis on the topics, markets and companies critical to your organization.